Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Wall Street Opens Lower as Covid-19 Fears Weigh Again; Dow Down 150 Pts

Published 08/18/2021, 09:34 AM
Updated 08/18/2021, 09:42 AM
© Reuters.

© Reuters.

By Geoffrey Smith 

Investing.com -- U.S. stock markets opened mostly lower again Wednesday, with cyclical and reopening stocks underperforming amid fear that the delta variant of the Covid-19 coronavirus could yet derail the global economic recovery. 

A sharp drop in housing starts in July, pointing to a further cooling off of the housing market under price and supply chain pressures, also hurt the mood, although building permits recovered after falling in June.

"The signal from the fall in sales is unambiguous," said Pantheon Macroeconomics Ian Shepherdson. "Both permits and starts are likely to fall over the next few months. Housing demand has reverted to its pre-Covid level, so construction activity needs to drop further."

By 9:40 AM ET (1340 GMT), the Dow Jones Industrial Average was down 147 points, or 0.4% at 35196 points. The S&P 500 was down 0.2% and the Nasdaq Composite outperformed, staying roughly unchanged.

Lowe’s Companies (NYSE:LOW) stock was the standout performer among blue chips in early trade, rising 7.0% after the retailer raised its forecast for the year on the back of a strong second quarter. While revenue from amateur home improvement items weakened as expected, it was more than offset by increased buying from business customers, notably on big-ticket tools. By contrast, Target (NYSE:TGT) stock fell even though the retailer beat expectations for profit and announced a new buyback program.

Virpax Pharmaceuticals (NASDAQ:VRPX) continued its stellar rise, leaping another 85% after the Food and Drug Administration sent it a written response concerning an experimental drug aimed at creating antiviral barriers. The FDA's pre-investigational new drug response "provides an opportunity for open communication between the Sponsor and the FDA to discuss the IND development plan and to obtain the FDA’s guidance for clinical studies for the new drug candidate," according to Anthony Mack, chairman and CEO of Virpax, which listed earlier this year.

Elsewhere, Tencent Holdings (OTC:TCEHY) ADRs rebounded 3.5% on the back of better-than-expected quarterly earnings, having hit a 15-month low on Tuesday. The stock has still lost 43% from its peak earlier this year under the weight of a regulatory onslaught against its services, which continued on Wednesday as state authorities accused its WeChat messaging service of making illegal data transfers (along with over 40 other apps).

Pfizer (NYSE:PFE) stock rose 1.4% to a new all-time high amid reports that the U.S. will approve 'booster shots' for those already fully vaccinated, paving the way for a long-lasting boost to revenue from its Covid-19 vaccine.

ViacomCBS (NASDAQ:VIAC) stock meanwhile, rose 4.7% after the broadcaster said it will roll out a new subscription streaming service, Sky Showtime, in 20 European markets from next year. The project is a joint venture with Comcast (NASDAQ:CMCSA) whose stock fell 0.1%.

Attention is likely to switch later in the day to the release of the minutes from the Federal Reserve's last policy meeting, a release that will be scanned for early hints of a tightening of monetary policy that many expect to be flagged more clearly by Chairman Jerome Powell at the Fed's symposium in Jackson Hole next week. The release is due at 2:00 PM ET (1800 GMT).

Latest comments

the market was marginally bad, random possible reason assigned to blame for it
"covid fear" day 1, "stimulus hopes" day 2... the eternal loop
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.